Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by biggdoggon Apr 03, 2023 11:21am
128 Views
Post# 35376201

ISFCA clarity- economics paint clear path

ISFCA clarity- economics paint clear pathISFCA
Lets make assumptions on economics (WAG), which dictate what they should do, using the dry contrast in a bottle:
Assume making the product and bottling it costs $1.70/bottle
Third party barite = $1.95/bottle
Third party manufacturing costs = $3.40/bottle
Total cost = $7.05/ bottle selling for $8/bottle, 0.95/bottle profit = 12% gross profit
If they start with a warehouse and a bottle mixing line importing Chinese ba,
Bottling costs = $1.70, Ba cost $1.95, total cost = 3.65 profit=4.35 = 54% gross margin
FC in production = bottling cost $1.70, Ba cost $0.28, Total cost = $1.98 total profit = $6.02 = 75%
When you look at it this way, they need to Get FC going asap, but if capital is limited, they should start by buying the equipment to make this stuff using Chinese. Surely the capX will be smaller by starting this way, lower dilution to get high margin cash flow, then get FC going. That’s how I would do it. Go rent a warehouse, buy the bottle filling equipment and start making money. No idea on the gmp hurdels doing this, but, Giddy Up Voy, lets go!!
<< Previous
Bullboard Posts
Next >>